Skip to main content
micro-community-banner
 
  • Saved

made a Post

Impact of depression on adherence to lenalidomide plus low-dose dexamethasone in patients with relapsed or refractory myeloma - PubMed

Patients with depression had a substantially high risk of poor adherence compared to patients without depression. Given that Rd treatment is mainly offered by outpatient clinics, active interventions to reduce ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/33575840/

  • Saved

made a Post

Synergistic interaction between HDAC and MCL-1 inhibitors through downregulation of BCL-XL in multiple myeloma - PubMed

doi: 10.3324/haematol.2020.277152. Online ahead of print. 1 Department of Medicine I, Wilhelminen Cancer Research Institute, Clinic Ottakring, Vienna, Austria; Recipient of a DOC Fellowship of the Austrian Academy of Sciences ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/33910332/

  • Saved

made a Post

Genetic Predictors of Mortality in Multiple Myeloma | TACG

Multiple myeloma (MM) is a hematologic malignancy characterized by the proliferation of clonal plasma cells. The disease is virtually always preceded by an asymptomatic stage named monoclonal gammopathy of undetermined ..... see more

Source : https://www.dovepress.com/genetic-predictors-of-mortality-in-patients-with-multiple-myeloma-peer-reviewed-fulltext-article-TACG

  • Saved

Commented on 's Post

Clinical outcomes and complications of surgical interventions for multiple myeloma lesions in the extremities and pelvis: A retrospective clinical study - PubMed

Objective: This study aimed to assess the pain and functional status of patients who underwent various surgical interventions for the stabilization of selected multiple myeloma (MM) lesions in the extremities ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/33847579/

Show More Comments

  • 1 week 3 days
    Location rather than the disease seems to best reflect the outcome of surgical intervention for skeletal related cancer complications
  • Saved

Commented on 's Post

Pembrolizumab plus pomalidomide and dexamethasone for relapsed or refractory multiple myeloma (KEYNOTE-183): subgroup analysis in Japanese patients - PubMed

The global, randomized, open-label KEYNOTE-183 phase 3 study was closed early after an interim analysis showed unfavorable risk-benefit when pembrolizumab was added to pomalidomide and dexamethasone in patients with relapsed ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/33856638/

Show More Comments

  • 1 week 3 days
    Small numbers in this retrospective analysis. At most hypothesis generating but seems unlikely that this will see additional work
  • Saved

Commented on 's Post

Bleeding Diathesis in Multiple Myeloma: A Rare Presentation of a Dreadful Emergency With Management Nightmare - PubMed

Multiple myeloma is a neoplastic disorder of plasma cells. An abnormal coagulation profile, though commonly seen in multiple myeloma, can rarely manifest as life-threatening hemorrhagic complications. Bleeding tendencies in multiple ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/33880309/

Show More Comments

  • 1 week 3 days
    This is a case report of a very rare complication of a relatively common disease. Report reflects the fact that malignant hematologists sometimes have to work through complex benign hematological Show More
  • Saved

Commented on 's Post

Dental pathologies in tumor patients with bone metastases or multiple myeloma scheduled for antiresorptive therapy - PubMed

doi: 10.2217/fon-2020-1240. Online ahead of print. 1 University Hospital for Cranio-Maxillofacial & Oral Surgery, A-6020, Innsbruck, Austria. 2 University Hospital for Dental Prosthetics & Restorative Dentistry, A-6020, Innsbruck, Austria. 3 ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/33880956/

Show More Comments

  • 1 week 3 days
    This article seems to reinforce the recommended practice to have patients obtain a baseline dental evaluation prior to bone antiresorptive therapy in myeloma given the high frequency of baseline issues Show More
  • Saved

Commented on 's Post

SARS-CoV-2 Vaccines in Patients With Multiple Myeloma

COVID-19 pandemic has led to an unprecedented need to develop an effective and safe vaccine in a timely manner. SARS-CoV-2 binds to human cells via the spike (S) protein, which ..... see more

Source : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7892292/

Show More Comments

  • 1 week 3 days
    Unfortunately there is limited information on vaccine efficacy or aes in myeloma and other cancers but given the rates of severe illness, adherence to the current guidelines certainly makes sense Show More
  • Saved

Commented on 's Post

tRNA-derived fragments and their roles in multiple myeloma | OTT

Multiple myeloma (MM) is the second most common hematological malignancy and is characterized by the accumulation of malignant plasma cells in the bone marrow. With the advent of new drugs, ..... see more

Source : https://www.dovepress.com/expression-profiles-of-trna-derived-fragments-and-their-potential-role-peer-reviewed-fulltext-article-OTT

Show More Comments

  • 1 week 3 days
    Interesting area of research identifying rna sequences that may play a role in myeloma pathogenesis
  • Saved

Commented on 's Post

Efficacy and Safety of CAR-T Therapy for Relapse or Refractory Multiple Myeloma: A systematic review and meta-analysis - PubMed

1 Department of Hematology, The Third Xiangya Hospital, Central South University, Changsha, Hunan, P.R. China. 2 Institute of Reproductive and Stem Cell Engineering, School of Basic Medical Science, Central South ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/33746596/

Show More Comments

  • 1 week 3 days
    It will be interesting to see, now that there is an fda approved myeloma car, what the uptake of this therapy will be in the real world as providers weigh Show More
  • Saved

Commented on 's Post

Show More Comments

  • 2 weeks 1 day
    Key points • Dutch researchers assessed the optimal sequence of treatment for patients with non-transplant eligible (NTE) multiple myeloma (MM) from patient, physician, and society vantage points. They assessed 30 treatment sequences, Show More
  • Saved

made a Post

Immune-related expression profiles of bisphosphonates-related osteonecrosis of the jaw in multiple myeloma - PubMed

Objective: To investigate the immune cellular and genomic profiles of bisphosphonates-related osteonecrosis (BRONJ) of the jaw and excavate potential small molecule drugs. Methods and materials: The genomic profile of a ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/33849701/

  • Saved

made a Post

Employment of Artificial Intelligence Based on Routine Laboratory Results for the Early Diagnosis of Multiple Myeloma - PubMed

Objective: In order to enhance the detection rate of multiple myeloma and execute an early and more precise disease management, an artificial intelligence assistant diagnosis system is developed. see more

Source : https://pubmed.ncbi.nlm.nih.gov/33854961/

  • Saved

Commented on 's Post

Cyclopamine sensitizes multiple myeloma cells to circularly permuted TRAIL-induced apoptosis - PubMed

Tumor necrosis factor related apoptosis inducing ligand (TRAIL) is a promising anti-myeloma drug prototype. The aim of the present study was to investigate the synergistic effects of cyclopamine and circularly ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/33732371/

Show More Comments

  • 3 weeks 2 days
    Interesting pharmacologic study demonstrating dual agent inhibition of myeloma cells. Further work hopefully will be done to confirm that this is a clinically relevant pathway
  • Saved

Commented on 's Post

A Review of Chimeric Antigen Receptor T-Cell Therapy for Myeloma and Lymphoma - PubMed

1 Plasma Cell Disorders Division, Department of Hematologic Oncology & Blood Disorders, Levine Cancer Institute/Atrium Health, Charlotte, NC, USA. 2 Lymphoma Division, Department of Hematologic Oncology & Blood Disorders, Levine ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/33814917/

Show More Comments

  • 3 weeks 2 days
    A very nice review of car T cell therapy as pertains to what are likely to be the most common indications in the very near future
  • Saved

Commented on 's Post

Quality of control groups in randomised trials of multiple myeloma enrolling in the USA: a systematic review - PubMed

To our knowledge, no study has evaluated the quality of control groups in randomised controlled trials of multiple myeloma. We aimed to do a systematic review of randomised controlled trials ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/33770485/

Show More Comments

  • 3 weeks 3 days
    Kudos to the authors for a comprehensive review of a group of patients that often doesn’t get a critical analysis ....
  • Saved

Commented on 's Post

Evaluation of Sustained Minimal Residual Disease Negativity With Daratumumab-Combination Regimens in Relapsed and/or Refractory Multiple Myeloma: Analysis of POLLUX and CASTOR

PURPOSE In relapsed and/or refractory multiple myeloma, daratumumab reduced the risk of progression or death by > 60% in POLLUX (daratumumab/lenalidomide/dexamethasone [D-Rd]) and CASTOR (daratumumab/bortezomib/dexamethasone [D-Vd]). Minimal residual disease (MRD) ..... see more

Source : https://ascopubs.org/doi/full/10.1200/JCO.20.01814

Show More Comments

  • 3 weeks 3 days
    This study adds to a growing literature base on use of mrd prognostically in myeloma ...it will be interesting to see if this translates into predictive utility as well
Mark Fesler Commented on a Post
  • Saved

Belantamab mafodotin FD: New treatment regimens for multiple myeloma

March is Multiple Myeloma Awareness Month and this is an exciting time due to recently approved therapies for multiple myeloma.

1. Selinexor, an XPO1 inhibitor, was first approved in combination with dexamethasone for penta-refractory patients (refractory to two protease inhibitors, two immunomodulators and an anti-CD38 monoclonal antibody) and recently received a supplementary approval in combination with bortezomib and dexamethasone for second-line or later multiple myeloma.

2. Belantamab mafodotin, an antibody-drug conjugate targeting BCMA, is approved for triple-class exposed patients that have been treated with at least four prior therapies including a protease inhibitor, an immunomodulator and an anti-CD38 monoclonal antibody.

3. Melphalan-flufenamide, a peptide conjugated alkylating drug, was approved for triple-refractory multiple myeloma patients that have been treated with at least four prior therapies.

Which of these regimens will have the greatest impact on your practice? Are there certain groups of patients better suited to a given therapy?

Sources:

Selinexor FDA label

Belantamab mafodotin FDA label

Melphalan-flufenamide FDA label

Show More Comments

  • 3 weeks 3 days
    Most excited about belantamab given ORR and novel mechanism of action. Seems that melphalan-flufenamide would be best suited for those patients who had long remissions from prior cytotoxic therapy. Show More
  • Saved

Commented on 's Post

The BCMA-Targeted Fourth-Generation CAR-T Cells Secreting IL-7 and CCL19 for Therapy of Refractory/Recurrent Multiple Myeloma

Chimeric antigen receptor (CAR) technology has revolutionized cancer treatment, particularly in malignant hematological tumors. Currently, the BCMA-targeted second-generation CAR-T cells have showed impressive efficacy in the treatment of refractory/relapsed multiple ..... see more

Source : https://doi.org/10.3389/fimmu.2021.609421

Show More Comments

  • 3 weeks 3 days
    This very limited experience with an armored CAR T is exciting given the ongoing unmet need for improved myeloma therapy
  • Saved

Commented on 's Post

Downregulation of ITGA6 confers to the invasion of multiple myeloma and promotes progression to plasma cell leukaemia - PubMed

doi: 10.1038/s41416-021-01362-5. Online ahead of print. 1 Department of Cell Biology, School of Biology & Basic Medical Sciences, Soochow University, Suzhou, China. 2 Department of Ophthalmology, The Second Affiliated Hospital ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/33785876/

Show More Comments

  • 3 weeks 3 days
    This may be the first study defining the importance of this protein ITGA6 in myeloma. An interesting inverse correlation with disease aggressiveness ...